Genetic Subtypes and Outcome of Patients Aged 1 to 45 Years Old With Acute Lymphoblastic Leukemia in the NOPHO ALL2008 Trial

Ulrika Norén-Nyström1,*, Mette K. Andersen2, Gisela Barbany3, Vaidas Dirse4, Martine Eilert-Olsen5, Marie Engvall6, Arja Harila-Saari7, Mats Heyman8,9, Randi Hovland10, Satu Häikiö11, Jón J. Jónsson12,13, Ritva Karhu14, Eigil Kjeldsen15, Anna Norberg16, Birgitte S. Preiss17, Kati Pulkkinen18, Petter Quist-Paulsen19, Hannele Räsänen20, Kjeld Schmiegelow21, Anne Seitsonen22, Helene Sjögren23, Pille Tammur24, Bertil Johansson25,26,*

[1]  Diane A. Flasch,et al.  The genomic landscape of pediatric acute lymphoblastic leukemia , 2022, Nature Genetics.

[2]  J. Esteve,et al.  Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the , 2021, Leukemia.

[3]  M. Mohty,et al.  Acute lymphoblastic leukaemia , 2020, The Lancet.

[4]  L. Osnes,et al.  T-cell acute lymphoblastic leukemia in patients 1–45 years treated with the pediatric NOPHO ALL2008 protocol , 2019, Leukemia.

[5]  Rawan Faramand,et al.  t(4;11)(q21;q23) KMT2A/AFF1 , 2018, Atlas of Genetics and Cytogenetics in Oncology and Haematology.

[6]  H. Marquart,et al.  Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years. , 2018, Blood.

[7]  T. Klausen,et al.  Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia , 2018, Leukemia.

[8]  A. Moorman.  Time for ALL adults to catch up with the children. , 2017, Blood.

[9]  B. Johansson,et al.  Pediatric T‐cell acute lymphoblastic leukemia , 2017, Genes, chromosomes & cancer.

[10]  A. Moorman.  New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia , 2016, Haematologica.

[11]  C. Harrison,et al.  Blood Spotlight on iAMP21 acute lymphoblastic leukemia (ALL), a high-risk pediatric disease. , 2015, Blood.

[12]  T. Klausen,et al.  Risk group assignment differs for children and adults 1–45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL‐2008 protocol , 2013, European journal of haematology.

[13]  B. Johansson,et al.  The frequency and prognostic impact of dic(9;20)(p13.2;q11.2) in childhood B-cell precursor acute lymphoblastic leukemia: results from the NOPHO ALL-2000 trial , 2011, Leukemia.

[14]  K. Schmiegelow,et al.  Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia , 2010, Leukemia.

[15]  A. Hall,et al.  Variable breakpoints target PAX5 in patients with dicentric chromosomes: A model for the basis of unbalanced translocations in cancer , 2008, Proceedings of the National Academy of Sciences.

[16]  S. Schnittger,et al.  dic(9; 20): A new recurrent chromosome abnormality in adult acute lymphoblastic leukemia , 1995, Genes, chromosomes & cancer.

[17]  K. Schmiegelow,et al.  Results of NOPHO ALL 2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia , 2022 .